Tissue and Pathology Resources

该项目将使用人类肉瘤标本进行转化研究， 改善人类肉瘤的治疗。肉瘤病理学和组织采购核心将 为SPORE研究人员提供来自SPORE和肉瘤治疗患者的高质量组织样本 研究与合作联盟（SARC）相关机构。标准化和集中化 已经建立了裂变材料采购、质量控制、加工、储存和 将样本分发给各个研究者，并将确保根据 样本委员会制定的准则。SarCore的功能将包括样本 从参与的SARC机构采购、加工、储存、组织病理学审查、检测和 病理学数据库的管理以及向项目分发特征良好的标本 投资者全国儿童医院（俄亥俄州哥伦布）的生物病理学中心（BCP）将协助 由当地顾问Nilsa Ramirez博士处理前瞻性临床样本， 这个grant。电子数据库与生物统计和临床试验核心数据库集成，包含 所有样本的病理和临床记录，存储和分发给个体调查者， 并包括各个SPORE项目的结果，以促进SarCore对 在这个SPORE和合作机构的投资者的需求。这些资源也将提供给 供将来在NCI CaBIG协议下使用。两名病理学家（Czerniak博士和Lazar博士）， 肉瘤病理学、生物学和核心手术的所有方面，包括组织病理学评价， 实验和质量控制，将共同指导该设施。他们将得到马特货车德赖恩博士的支持 （斯坦福大学）和克里斯托弗弗莱彻（哈佛），都具有丰富的经验，肉瘤病理学和 学术研究。货车de Rijn博士是高通量分析肉瘤生物标志物的专家， 虽然弗莱彻博士的临床诊断意见被广泛认为是明确的， 复杂的竞技场。这个集中的综合设施将提供实验支持， 合作的多学科和转化的研究项目outined在这个孢子的建议。 该中心的所有五名病理学家在这方面都有丰富的经验。这种支持是必要的， 罕见的未充分研究的孤儿恶性肿瘤家族，只有多机构合作才能促进 人类肿瘤组织资源的获取对于在这种未充分研究的疾病中取得进展至关重要。

The projects of this SPORE will use human sarcoma specimens for translational research directed toward improving the treatment of human sarcomas. The Sarcoma Pathology and Tissue Procurement Core will provide SPORE investigators with high-quality tissue samples from pafients treated at SPORE and Sarcoma Alliance for Research and Collaboration (SARC) associated institutions. Standardized and centralized procedures have been established for fissue procurement, quality control, and processing, storage, and distribufion of samples to individual investigators and will ensure opfimal use of the samples according to the guidelines established by the Specimen Committee. Funcfions of SarCore will include specimen procurement from participating SARC insfitufions, processing, storage, histopathologic review, tesfing, and management of pathological databases as well as distribution of well-characterized specimens to project invesfigators. The Biopathology Center (BCP) at Nationwide Children's Hospital (Columbus, OH) will faciliate processing of prospective clinical samples with Dr. Nilsa Ramirez as a local consultant there supported by this grant. The electronic database is integrated with the Biostafisfics and Clinical Trials Cores and contains both pathological and clinical records of all samples, both stored and distributed to individual invesfigators, and includes the results of individual SPORE projects to facilitate the efficient response of SarCore to the needs of invesfigators in this SPORE and at collaborating institufions. These resources will also be available for future use under the NCI CaBIG¿ protocol. Two pathologists (Drs. Czerniak and Lazar) with expertise in sarcoma pathology, biology and in all aspects of Core operafions, including histopathologic evaluation, experimentafion and quality control, will co-direct the facility. They will be supported by Drs. Matt van de Rijn (Stanford) and Christopher Fletcher (Harvard), all with extensive experience in sarcoma pathology and translafional research. Dr. van de Rijn is expert in high-throughput analysis sarcoma biomarkers and sarcoma pathobiology while Dr. Fletcher's clinical diagnostic opinions are widely regarded as definitive In this complex arena. This centralized comprehensive facility will provide experimental support and close collaborafion forthe mulfidisciplinary and translational research projects oufiined in this SPORE proposal. All five pathologists in this core has extensive experience in this regard. Such support is necessary in this rare family of understudied orphan malignancies where only mulfi-institufional cooperafion can facilitate the acquisifion of human tumor tissue resources vital to make progress in this understudied disease.